source
- Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pillThree years after Robert Hoffman sold XinThera to Gilead, the veteran Pfizer chemist has unveiled his latest venture.Fierce Biotech · 1d ago↗ source
- Definium's LSD-based therapy shows strong Phase 3 results in generalized anxiety disorderDefinium Therapeutics reported that its LSD-derived oral tablet, DT120, met its primary endpoint in a Phase 3 trial for generalized anxiety disorder. The study enrolled over 200 participants and co…